Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma
Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma have?
Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma has 0 citations in the OpenAlex counts ScholarIQ stores.
When was Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma published?
Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma has 2022 year in the ScholarIQ index.
What is the open-access status of Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma?
Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma has diamond oa status in the ScholarIQ index.
What is the DOI of Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma?
The DOI for Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma is on the source record.
What is the OpenAlex record for Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma?
The OpenAlex for Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma is on the source record.